Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VICL

Vical (VICL) Stock Price, News & Analysis

Vical logo

About Vical Stock (NASDAQ:VICL)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.68
$3.15
52-Week Range
N/A
Volume
35,024 shs
Average Volume
1.44 million shs
Market Capitalization
$21.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.

Receive VICL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vical and its competitors with MarketBeat's FREE daily newsletter.

VICL Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More Headlines

VICL Stock Analysis - Frequently Asked Questions

Vical Incorporated (NASDAQ:VICL) released its quarterly earnings results on Tuesday, February, 19th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.17). The biotechnology company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.04 million. Vical had a negative trailing twelve-month return on equity of 29.46% and a negative net margin of 1,002.10%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vical investors own include Caladrius Biosciences (CLBS), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Cytori Therapeutics (CYTX), Synergy Pharmaceuticals (SGYP), CTI BioPharma (CTIC) and Idera Pharmaceuticals (IDRA).

Company Calendar

Last Earnings
2/19/2019
Today
5/25/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VICL
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-16,250,000.00
Net Margins
-1,002.10%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.62 million
Price / Cash Flow
N/A
Book Value
$1.82 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$21.01 million
Optionable
Not Optionable
Beta
0.32
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:VICL) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners